Michael V. Seiden, M.D., Ph.D., Takes Office As Fox Chase Cancer Center President and CEO
PHILADELPHIA (June 1, 2007) — , has taken office as president and CEO of Fox Chase Cancer Center.
The board of directors of Fox Chase Cancer Center selected Seiden on March 22, 2007 to replace Robert C. Young, MD, who stepped down and now serves as chancellor at Fox Chase.
Seiden, a board-certified medical oncologist, previously led the gynecologic cancer program at Dana-Farber/Harvard Cancer Center and served as chief of the clinical research unit in Massachusetts General Hospital's Division of Cancer Medicine.
Seiden's research focuses on clinical and translational studies in ovarian cancer. His laboratory has also begun studies to identify and characterize the ovarian-cancer stem cell.
Seiden's previous responsibilities included serving as associate professor of medicine at Harvard, physician coordinator of the cancer stem-cell project at Dana-Farber/Harvard Cancer Center (DF/HCC), principal investigator for the ovarian cancer tumor biology laboratory at Massachusetts General and co-principal investigator of DF/HCC's NCI grant for a Specialized Program of Research Excellence (SPORE) in ovarian cancer.
Born in Queens, N.Y., Seiden received his undergraduate degree magna cum laude at Oberlin College in Oberlin, Ohio, in 1980. In 1986, he simultaneously earned his M.D. and Ph.D. through the Medical Science Training Program in Immunology at Washington University in St. Louis, Mo.
Seiden completed his internship and residency in medicine at Massachusetts General, serving as chief resident in 1991. He was a fellow in medicine at Harvard, held a three-year clinical fellowship in medical oncology at Dana-Farber Cancer Institute and also completed a one-year bone-marrow transplant fellowship there. He completed a postdoctoral fellowship in molecular pathology at Harvard's Brigham and Women's Hospital. Seiden joined the Harvard medical faculty as an instructor in 1991 and became an assistant professor in 1994 before becoming associate professor in 2003.
His recent honors include being named as Massachusetts Breast Cancer Scholar in 1995 and again in 2000 and 2001. He has successfully competed for a Clinical Interface Award funded through the Doris Duke Foundation. He has also been an invited lecturer at the international ovarian cancer forums sponsored by England's Helene Harris Memorial Trust in 2001, 2005 and 2007. Seiden is active in many professional organizations and editorial boards and serves on national and international committees and advisory boards.
Fox Chase Cancer Center, part of the Temple University Health System, is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence four consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. For more information, call 1-888-FOX CHASE or (1-888-369-2427).
Media inquiries only, please contact Jeremy Moore at 215-728-2700.